Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $144 at Wedbush, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts BHVN Hot Sheet
Price: $15.61 --0%
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Wedbush analyst Laura Chico lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $144.00 (from $152.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biohaven Pharma (BHVN) PT Raised to $21 at Morgan Stanley
- Carborundum Universal Ltd (CU:IN) PT Raised to INR980 at Macquarie
- PT Telekomunikasi Indonesia Tbk (TLKM:IJ) (TLKMF) PT Lowered to IDR2,200 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
